Andrew Heath, Chief Executive of Protherics commented: "The agreement with Nobilon today supports our excitement about the prospects for our CoVaccine HT adjuvant, which we are also incorporating in our Angiotensin Therapeutic Vaccine. We also have considerable interest from other external parties to use our adjuvant in their vaccines across a range of other potential indications."
About the CoVaccine HT(TM) Adjuvant
An adjuvant is a substance which enhances the immune response and so helps maximise the production of antibodies. The CoVaccine HT(TM) adjuvant is a sucrose fatty acid sulphate ester that increases both humoral and cell-mediated immune responses to experimental vaccines following intramuscular administration. In nonclinical studies, the adjuvant has been well-tolerated with no limiting local toxicity, and has produced encouraging immune responses.
Nobilon International BV, part of Organon, a biopharmaceutical business unit of Akzo Nobel, was founded in 2003. It has production and R&D facilities in Boxmeer and Oss, the Netherlands. The biotechnology company is dedicated to develop, produce and market human vaccines against infectious diseases, building on existing expertise within sister companies Intervet and Organon. Nobilon focuses on respiratory and traveler's diseases. One of its core expertises is large scale cell culture production of viruses, including influenza. Nobilon currently employs approximately 75 staff in production and R&D. http://www.nobilon.com
Protherics (LSE: PTI, NASDAQ: PTIL) is a leading biopharmaceutical
company focused on the development, manufacture and marketing of
specialised products for critical care and cancer. The Company's strategy
is to use the revenues generated from its marketed and out-licensed
products to help fund the advancement of its broad, late stage pipeline.
|SOURCE N.V. Organon|
Copyright©2007 PR Newswire.
All rights reserved